Literature DB >> 12429159

The valuation of the International Prostate Symptom Score (IPSS) for use in economic evaluations.

Esther T Kok1, Joseph McDonnell, Elly A Stolk, Herman J Stoevelaar, Jan J V Busschbach.   

Abstract

OBJECTIVE: Lower Urinary Tract Symptoms (LUTS) suggestive of Benign Prostatic Obstruction (BPO) cause a reduction in quality of life, but the magnitude of that reduction cannot be estimated empirically. This is because survey instruments currently available merely sum the symptoms found, but do not value their impact on quality of life. It is therefore difficult to determine whether the effects of treatments for LUTS suggestive of BPO justify the costs. This complicates economic evaluations.
METHODS: We valued the impact on quality of life of patients with LUTS suggestive of BPO, by valuing health states defined by the International Prostate Symptom Score (IPSS) using the time trade-off (TTO). TTO values ranged from 1.0 for perfect health to 0.0 for the value of death, and can be used to calculate Quality-Adjusted Life Years (QALYs), the preferred outcome measure in health economics.
RESULTS: We reduced the number of health states defined by the IPSS using factor analysis. The resulting nine health states were valued by a representative sample of the general public (N=170) using TTO. The worst IPSS health state was valued at 0.87.
CONCLUSION: The values for health states defined by the IPSS revealed that LUTS suggestive of BPO has a mild impact on quality of life. The valuation of the IPSS facilitates economic evaluations of treatments for LUTS suggestive of BPO, because QALYs (the preferred outcome measure in health economics) can be determined empirically.

Entities:  

Mesh:

Year:  2002        PMID: 12429159     DOI: 10.1016/s0302-2838(02)00403-7

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  13 in total

Review 1.  The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment.

Authors:  Donna Rowen; John Brazier; Roberta Ara; Ismail Azzabi Zouraq
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

2.  The use of disease-specific outcome measures in cost-utility analysis: the development of Dutch societal preference weights for the FACT-L scale.

Authors:  Leida M Lamers; Carin A Uyl-de Groot; Ivonne Buijt
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

Review 3.  The long-term cost effectiveness of treatments for benign prostatic hyperplasia.

Authors:  Rachael L DiSantostefano; Andrea K Biddle; John P Lavelle
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  Dimensions Used in Instruments for QALY Calculation: A Systematic Review.

Authors:  Moustapha Touré; Christian R C Kouakou; Thomas G Poder
Journal:  Int J Environ Res Public Health       Date:  2021-04-21       Impact factor: 3.390

5.  The impact of adding an extra dimension to a preference-based measure.

Authors:  John Brazier; Donna Rowen; Aki Tsuchiya; Yaling Yang; Tracy A Young
Journal:  Soc Sci Med       Date:  2011-06-02       Impact factor: 4.634

6.  Estimating a preference-based index for a menopause specific health quality of life questionnaire.

Authors:  John E Brazier; Jennifer Roberts; Maria Platts; York F Zoellner
Journal:  Health Qual Life Outcomes       Date:  2005-03-15       Impact factor: 3.186

7.  Open urethroplasty versus endoscopic urethrotomy--clarifying the management of men with recurrent urethral stricture (the OPEN trial): study protocol for a randomised controlled trial.

Authors:  Rachel Stephenson; Sonya Carnell; Nicola Johnson; Robbie Brown; Jennifer Wilkinson; Anthony Mundy; Steven Payne; Nick Watkin; James N'Dow; Andrew Sinclair; Rowland Rees; Stewart Barclay; Jonathan A Cook; Beatriz Goulao; Graeme MacLennan; Gladys McPherson; Matthew Jackson; Tim Rapley; Jing Shen; Luke Vale; John Norrie; Elaine McColl; Robert Pickard
Journal:  Trials       Date:  2015-12-30       Impact factor: 2.279

8.  Surgical treatments for men with benign prostatic enlargement: cost effectiveness study.

Authors:  Nigel Armstrong; Luke Vale; Mark Deverill; Ghulam Nabi; Samuel McClinton; James N'Dow; Robert Pickard
Journal:  BMJ       Date:  2009-04-16

Review 9.  Social, economic, and health utility considerations in the treatment of overactive bladder.

Authors:  Emilio Sacco; Daniele Tienforti; Alessandro D'Addessi; Francesco Pinto; Marco Racioppi; Angelo Totaro; Daniele D'Agostino; Francesco Marangi; Pierfrancesco Bassi
Journal:  Open Access J Urol       Date:  2010-02-11

10.  Long-term safety, health and mental status in men with vasectomy.

Authors:  Kai Zhao; Li Wu; Xiangbin Kong; Yaoping Chen; Honggang Li; Yiqun Gu; Xuejun Shang; Chengliang Xiong
Journal:  Sci Rep       Date:  2018-10-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.